| 11.42 -0.42 (-3.55%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.59  |
1-year : | 20.35 |
| Resists | First : | 15.06 |
Second : | 17.43 |
| Pivot price | 14.41 |
|||
| Supports | First : | 11.23 |
Second : | 9.35 |
| MAs | MA(5) : | 12.26 |
MA(20) : | 14.88 |
| MA(100) : | 13.67 |
MA(250) : | 10.53 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 12.4 |
| RSI | RSI(14): 26.9 |
|||
| 52-week | High : | 17.43 | Low : | 5.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMUX ] has closed above bottom band by 9.4%. Bollinger Bands are 106.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.96 - 12.05 | 12.05 - 12.11 |
| Low: | 11.03 - 11.14 | 11.14 - 11.22 |
| Close: | 11.27 - 11.42 | 11.42 - 11.53 |
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Fri, 11 Sep 2026
Dr. Duane Nash resigns from Immunic board; board reduced to nine members - TradingView
Thu, 10 Sep 2026
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10 - Seeking Alpha
Wed, 09 Sep 2026
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Wed, 09 Sep 2026
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
Tue, 25 Aug 2026
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Thu, 13 Aug 2026
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 70.6 (%) |
| Shares Short | 1,280 (K) |
| Shares Short P.Month | 1,410 (K) |
| EPS | -3.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.9 % |
| Return on Equity (ttm) | -138.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -3.22 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|